285 related articles for article (PubMed ID: 26951563)
21. Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder.
Matthes F; Massari S; Bochicchio A; Schorpp K; Schilling J; Weber S; Offermann N; Desantis J; Wanker E; Carloni P; Hadian K; Tabarrini O; Rossetti G; Krauss S
ACS Chem Neurosci; 2018 Jun; 9(6):1399-1408. PubMed ID: 29506378
[TBL] [Abstract][Full Text] [Related]
22. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
23. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
24. Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington's disease.
Aviner R; Lee TT; Masto VB; Li KH; Andino R; Frydman J
Nat Cell Biol; 2024 Jun; 26(6):892-902. PubMed ID: 38741019
[TBL] [Abstract][Full Text] [Related]
25. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.
Choi DE; Shin JW; Zeng S; Hong EP; Jang JH; Loupe JM; Wheeler VC; Stutzman HE; Kleinstiver B; Lee JM
Elife; 2024 Jun; 12():. PubMed ID: 38869243
[TBL] [Abstract][Full Text] [Related]
26. Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1.
Mouro Pinto R; Arning L; Giordano JV; Razghandi P; Andrew MA; Gillis T; Correia K; Mysore JS; Grote Urtubey DM; Parwez CR; von Hein SM; Clark HB; Nguyen HP; Förster E; Beller A; Jayadaev S; Keene CD; Bird TD; Lucente D; Vonsattel JP; Orr H; Saft C; Petrasch-Parwez E; Wheeler VC
Hum Mol Genet; 2020 Aug; 29(15):2551-2567. PubMed ID: 32761094
[TBL] [Abstract][Full Text] [Related]
27. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
[TBL] [Abstract][Full Text] [Related]
28. The long non-coding RNA NEAT1 is elevated in polyglutamine repeat expansion diseases and protects from disease gene-dependent toxicities.
Cheng C; Spengler RM; Keiser MS; Monteys AM; Rieders JM; Ramachandran S; Davidson BL
Hum Mol Genet; 2018 Dec; 27(24):4303-4314. PubMed ID: 30239724
[TBL] [Abstract][Full Text] [Related]
29. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
30. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
Preisinger E; Jordan BM; Kazantsev A; Housman D
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
[TBL] [Abstract][Full Text] [Related]
31. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
[TBL] [Abstract][Full Text] [Related]
32. Copper enhances aggregational toxicity of mutant huntingtin in a Drosophila model of Huntington's Disease.
Lobato AG; Ortiz-Vega N; Zhu Y; Neupane D; Meier KK; Zhai RG
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166928. PubMed ID: 38660915
[TBL] [Abstract][Full Text] [Related]
33. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
Chen M; Wolynes PG
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
[TBL] [Abstract][Full Text] [Related]
34. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
Sugaya K
Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
[TBL] [Abstract][Full Text] [Related]
35. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.
Wilburn B; Rudnicki DD; Zhao J; Weitz TM; Cheng Y; Gu X; Greiner E; Park CS; Wang N; Sopher BL; La Spada AR; Osmand A; Margolis RL; Sun YE; Yang XW
Neuron; 2011 May; 70(3):427-40. PubMed ID: 21555070
[TBL] [Abstract][Full Text] [Related]
36. Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues.
Hoschek F; Natan J; Wagner M; Sathasivam K; Abdelmoez A; von Einem B; Bates GP; Landwehrmeyer GB; Neueder A
Mol Med; 2024 Mar; 30(1):36. PubMed ID: 38459427
[TBL] [Abstract][Full Text] [Related]
37. Assessing average somatic CAG repeat instability at the protein level.
Aviolat H; Pinto RM; Godschall E; Murtha R; Richey HE; Sapp E; Vodicka P; Wheeler VC; Kegel-Gleason KB; DiFiglia M
Sci Rep; 2019 Dec; 9(1):19152. PubMed ID: 31844074
[TBL] [Abstract][Full Text] [Related]
38. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis implicates the amyloid fibril as the toxic entity in Huntington's disease.
Drombosky KW; Rode S; Kodali R; Jacob TC; Palladino MJ; Wetzel R
Neurobiol Dis; 2018 Dec; 120():126-138. PubMed ID: 30171891
[TBL] [Abstract][Full Text] [Related]
40. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice.
Zheng S; Clabough EB; Sarkar S; Futter M; Rubinsztein DC; Zeitlin SO
PLoS Genet; 2010 Feb; 6(2):e1000838. PubMed ID: 20140187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
